Institutional Ownership
Ovid Therapeutics Inc
CUSIP 690469101COMOVIDQ1 2026
13D / 13G Filings
52
Schedule 13D/13G on record
Beneficial Filers
24
Distinct reporting persons
Largest Stake
13.0%
Max % of class reported
Institutional Holders
100
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
52 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Adar1 Capital Management, LLC | 13G | 13.0% | 9.28M | SEC |
| 2 | Jan 29, 2026 | Affinity Asset Advisors, LLC | 13G/A | 9.0% | 12.15M | SEC |
| 3 | Jan 8, 2026 | Federated Hermes, Inc. | 13G | 11.0% | 7.74M | SEC |
| 4 | Jan 5, 2026 | Point72 Asset Management, L.P. | 13G | 5.1% | 6.73M | SEC |
| 5 | Dec 18, 2025 | Ra Capital Management, L.P. | 13G | 9.9% | 13.26M | SEC |
| 6 | Dec 18, 2025 | Affinity Asset Advisors, LLC | 13G | 9.0% | 12.15M | SEC |
| 7 | Dec 9, 2025 | Takeda Pharmaceutical Company Limited | 13G/A | 12.3% | 8.78M | SEC |
| 8 | Dec 8, 2025 | Janus Henderson Group PLC | 13G | 10.0% | 7.11M | SEC |
| 9 | Jul 21, 2025 | Biotechnology Value Fund L P | 13G/A | — | 212.0K | SEC |
| 10 | Jul 17, 2025 | Blackrock, Inc. | 13G/A | 1.9% | 1.37M | SEC |
42 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Ovid Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 10.71M | $23.79M |
| 2 | Janus Henderson Group PLC | 10.71M | $23.73M |
| 3 | Affinity Asset Advisors, LLC | 10.64M | $23.61M |
| 4 | Eventide Asset Management, LLC | 9.92M | $22.02M |
| 5 | Adage Capital Partners Gp, L.L.C. | 6.16M | $13.68M |
| 6 | Balyasny Asset Management L.P. | 5.53M | $12.28M |
| 7 | Adar1 Capital Management, LLC | 4.54M | $10.09M |
| 8 | Saturn V Capital Management LP | 4.17M | $9.25M |
| 9 | Federated Hermes, Inc. | 3.57M | $7.93M |
| 10 | Ikarian Capital, LLC | 2.89M | $6.43M |